sellWeak10b5-1 plan
Dana Pizzuti sold $195k of CRNX
Chief Med and Dev Officer at Crinetics Pharmaceuticals, Inc.. 5,000 shares at an average of $39.07, traded Feb 3, 2025, filed Feb 5, 2025.
Warning score
0Value
$195k
5,000 shares
Holdings after
31,748
-14% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +12Trade size$195k at market
- +5Share of holdings soldSold 14% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-014557, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 3, 2025 | MOption exercise Common Stock10b5-1 | +5,000 | $16.89 | $84k | 36,748 | Feb 5, 2025 |
| Feb 3, 2025 | SOpen-market sale Common Stock10b5-1 | -5,000 | $39.07 | $195k | 31,748 | Feb 5, 2025 |
| Feb 3, 2025 | MOption exercise Stock option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 119,042 | Feb 5, 2025 |
Related signals
Other insiders at Crinetics Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $3.1M 97,483 shares | -49% | |
| 22Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $197k 5,770 shares | -5% | |
| 39Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $593k 17,338 shares | -5% | |
| 28Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $245k 7,162 shares | -8% | |
| 19Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $86k 2,515 shares | -3% | |
| 12Weak | Crinetics Pharmaceuticals, Inc. | Dana Pizzuti Chief Med and Dev Officer | $781k 15,000 shares | -34% | |
| 32Weak | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $576k 10,000 shares | -9% | |
| 13Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $28k 501 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.